Breaking News, Collaborations & Alliances

Sobi, Biogen Idec Revise Hemophilia Pact

Biogen assumes full development responsibilities and costs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sobi and Biogen Idec have updated their agreement regarding the development and commercialization of long-lasting recombinant factor VIII and factor IX hemophilia programs. Biogen has assumed full development responsibilities and costs, as well as manufacturing rights. Sobi will have commercial rights in Europe, Russia, Turkey and certain countries in the Middle East. Biogen has commercial rights for North America and for rest of the world markets. Following Biogen’s submission of a marketing a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters